Associated with document Ref.

Ares(2022)8240353 - 29/11/2022

Proposal Evaluation Form

EUROPEAN COMMISSION Evaluation Summary
Report - RIA First
Horizon Europe (HORIZON)
Stage actions
Call: HORIZON-JU-IHI-2022-02-two-stage
Type of action: HORIZON-JU-RIA
Proposal number: 101112006-1
Proposal acronym: CardioMate
Duration (months): 48
The Whole-Person, Digital Twin Approach to Prevention & Precision Care for Cardiovascular Conditions, Driven by
Proposal title:
AI & Multi-Modal Real-World Evidence and Data
Activity: HORIZON-JU-IHI-2022-02-01
Total eligible Grant
N. Proposer name Country % %
costs Requested
1 KONNEKT ABLE TECHNOLOGIES LIMITED IE 0 - 0 -
2 CapsicoHealthCare, Limited IE 0 - 0 -
3 SIEMENS SRL RO 0 - 0 -
4 SCIENTIFIC ACADEMY FOR SERVICE TECHNOLOGY EV DE 0 - 0 -
EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS
5 EL 0 - 0 -
EVTHINIS
GIOUMPITEK MELETI SCHEDIASMOS YLOPOIISI KAI POLISI
6 EL 0 - 0 -
ERGON PLIROFORIKIS ETAIREIA PERIORISMENIS EFTHYNIS
7 MEDONE RESEARCH SRL RO 0 - 0 -
8 Stamadianos and Partners Law Firm EL 0 - 0 -
9 S E&C IKE EL 0 - 0 -
REA GYNAIKOLOGIKI MAIEFTIKI CHEIROURGIKI
10 EL 0 - 0 -
THERAPEFTIKI DIAGNOSTIKI KLINIKI A.E
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION
11 ES 0 - 0 -
SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA
12 SERVICIO ANDALUZ DE SALUD ES 0 - 0 -
13 CARDIO MED SRL RO 0 - 0 -
14 CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE BE 0 - 0 -
15 FONDAZIONE ANT ITALIA ONLUS IT 0 - 0 -
SPITALUL CLINIC JUDETEAN DE URGENTA PIUS BRINZEU
16 RO 0 - 0 -
TIMISOARA
FUNDACION PARA LA FORMACION E INVESTIGACION DE
17 LOS PROFESIONALES DE LASALUD DE EXTREMADURA ES 0 - 0 -
FUNDESALUD
18 UNIVERSITE LYON 1 CLAUDE BERNARD FR 0 - 0 -
19 CHU HOPITAUX DE BORDEAUX FR 0 - 0 -
20 HOSPICES CIVILS DE LYON FR 0 - 0 -
  Total:   0   0  
Abstract:

101112006-1/CardioMate-29/11/2022-10:29:48 1/4
 Cardiomate project aims to drive personalized care platform combined with digital-twin concepts (digitization and interrogation) for CVD patients based on
multi-modal data sets representing lifestyle factors, remote patient monitoring, genomics, tissue-banks
Associatedand labdocument
with results. Cardiomate will enable multiple
Ref. Ares(2022)8240353 - 29/11/2022
timepoint assessments to ascertain the directionality and dimensionality of care pathways based up on learning from continuous electrocardiogram (ECG),
activity data from wearable devices, digital health applications and intake from clinical practices. Cardiomate will also leverage data from ‘open access’ systems
(with GDPR) such as biomarkers and electronic health records provided by several project participants (hospitals), adding to the knowledge base for prevention
and care. Cardiomate will enable risk stratification and demonstrate markers from wearables, imaging and intake-based screening of CVD conditions.
Caridomate will identify patient cohorts that respond differently to prevention and treatment of atherosclerotic cardiovascular disease (ASCVD) and HF in
clinical settings. The project will also identification of ASCVD and HF patients, for instance people with insulin resistance, diabetes, and obesity, into clinically
meaningful subgroups. Cardiomate will enable a wholistic overview of specific patient groups to personalize treatment.

Evaluation Summary Report

Evaluation Result

Total score: 11.50 (Threshold: 10)

Criterion 1 - Excellence

Score:  4.00 (Threshold: 3/5.00 , Weight: -)

The following aspects will be taken into account, to the extent that the proposed work corresponds to
the topic description in the work programme:
- Clarity and pertinence of the project’s objectives, and the extent to which the proposed work is
ambitious, and goes beyond the state of the art.
- Soundness of the proposed overall methodology.
The proposal addresses well all the key objectives and fits well with most of the call topic aims, especially for
secondary prevention. However, although a number of observational studies will be carried out, the extent by
which they may relate to improvement in the conduction of RCTs is not fully specified. Also, different
subpopulation/subgroups mentioned in the call topic, such as youth populations, are underrepresented in the
proposal. These are shortcomings.
CardioMate is a very ambitious proposal that goes well beyond the state-of-the-art. It is based on a holistic
approach which is well justified. It brings together principles of timely screening, early diagnoses, and digital
twin concepts to enable a comprehensive cloud-enabled multi-modal AI platform with real-world evidence to
prevent CVD. In addition, the proposal explicitly addresses socio-economic determinants and factors, which
are often neglected by current “one size fits all” risk prevention strategies. These are strengths.
The proposed methodology is robust and credible for creating a partnership with the pre-identified industry
consortium, as well as presenting evidence of the ability to develop and deploy trustworthy AI paradigms for
CVD prevention and self-management. This is a strength.
Although the issue of multimodal imaging is addressed, some of its aspects are not convincingly presented. For
example, there is limited information presented on the multimodality imaging in terms of methods used, or how
those will be applied for AI methods or studies. This is a shortcoming.
The methodology does not provide sufficient detail on how multimodal data can be integrated and interpreted
for individuals at risk. For example, it is not clear how clinical data (from hospital records) will be integrated
with other data sources (wearables, social/behaviour, genetics…) at a single individual level, given that the
different data pipelines might come from separate data sources. This is a shortcoming.
The work proposed is inherently multi- and interdisciplinary, meaningfully integrating the medical,
behavioural, sociological, and technical domains of the research. The consortium will engage with existing EU-
related working groups on the role of wearables in cardiovascular screening and diagnosis. This is a strength.
Engagement with regulatory authorities is considered, however specific information on their relations to
different implementation strategies is not clearly articulated. This is a minor shortcoming.
Data management, including data access and sharing, is appropriately described. The gender dimension is
equally well projected. The proposal formulates very well how open sciences practices are incorporated into the
proposed methodology.

Criterion 2 - Impact

Score:  3.50 (Threshold: 3/5.00 , Weight: -)

101112006-1/CardioMate-29/11/2022-10:29:48 2/4
 The following aspects will be taken into account:
- Credibility of the pathways to achieve the expected outcomes andwith
Associated impacts
documentspecified in the work
Ref. Ares(2022)8240353 - 29/11/2022
programme, and the likely scale and significance of the contributions due to the project.
The proposed pathways to achieve the expected outcomes and impacts are generally solid, credible and well
described. This is a strength.
The target groups for each outcome are well identified. There is a strength. However they are not broken down
into particular interest groups or segments of society. This is a minor shortcoming.
The likely scale and significance of each expected project outcome and contribution are properly addressed.
However, the definition and measurement metrics for the expected impact measures are not clearly established,
and some target values are quite over-ambitious (e.g. “5-20% improvement of personalised early risk
prediction” is not justified). This is a shortcoming.
Although a multidisciplinary team will be put together for the task of addressing potential barriers and their
mitigation actions, these have not been clearly identified. This is a shortcoming.

Criterion 3 - Quality and efficiency of the implementation

Score:  4.00 (Threshold: 3/5.00 , Weight: -)

The following aspects will be taken into account:

- Quality and effectiveness of the outline of the work plan.
- Capacity of each participant, and extent to which the consortium as a whole brings together the
necessary expertise.
The work plan is well described. The duration of each work package is well justified, and the individual work
packages proposed are well explained, meaningful and interconnected. These are strengths.
Each participant is well qualified and experienced, with solid references and brings sufficient benefits to the
consortium’s general efficiency. However, patient group representation within the consortium is only reflected
through proxies. This is a shortcoming.
The consortium brings together the expertise to complement the pre-identified industrial consortium in order to
create a planned successful public-private partnership, which is a strength. However, the contribution of the
pre-identified industry consortium in specific activities is not appropriately considered. This is a shortcoming.
The participants have access to the critical infrastructure needed to carry out the project. This is a strength.

Scope of the application

Status:  Yes

Comments (in case the proposal is out of scope)

Not provided

Exceptional funding

A third country participant/international organisation not listed in the General Annex to the Main Work
Programme may exceptionally receive funding if their participation is essential for carrying out the
project (for instance due to outstanding expertise, access to unique know-how, access to research
infrastructure, access to particular geographical environments, possibility to involve key partners in
emerging markets, access to data, etc.). (For more information, see the HE programme guide )
Please list the concerned applicants and requested grant amount and explain the reasons why.
Based on the information provided, the following participants should receive exceptional funding:
Not provided

101112006-1/CardioMate-29/11/2022-10:29:48 3/4
 Based on the information provided, the following participants should NOT receive exceptional
funding: Associated with document Ref. Ares(2022)8240353 - 29/11/2022
Not provided

Use of human embryonic stem cells (hESC)

Status:  No

If YES, please state whether the use of hESC is, or is not, in your opinion, necessary to achieve the
scientific objectives of the proposal and the reasons why. Alternatively, please state if it cannot be
assessed whether the use of hESC is necessary or not, because of a lack of information.
Not provided

Activities excluded from funding

Status:  No

If YES, please explain.

Not provided

Do no significant harm principle

Status:  Not applicable

If Partially/No/Cannot be assessed please explain

Not provided

Exclusive focus on civil applications

Status:  Yes

If NO, please explain.

Not provided

Artificial Intelligence

Status:  No

If YES, the technical robustness of the proposed system must be evaluated under the appropriate
criterion.
Overall comments

Not provided

101112006-1/CardioMate-29/11/2022-10:29:48 4/4
 Digitally sealed by the European Commission
Date: 2022.11.29 10:33:23 CET

This electronic receipt is a digitally signed version of the document submitted by your
organisation. Both the content of the document and a set of metadata have been digitally
sealed.

This digital signature mechanism, using a public-private key pair mechanism, uniquely
binds this eReceipt to the modules of the Funding & Tenders Portal of the European
Commission, to the transaction for which it was generated and ensures its full integrity.
Therefore a complete digitally signed trail of the transaction is available both for your
organisation and for the issuer of the eReceipt.

Any attempt to modify the content will lead to a break of the integrity of the electronic
signature, which can be verified at any time by clicking on the eReceipt validation
symbol.

More info about eReceipts can be found in the FAQ page of the Funding & Tenders
Portal.

(https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq)

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111